|Bid||6.70 x 3519200|
|Ask||6.88 x 165200|
|Day's range||6.70 - 7.30|
|52-week range||6.45 - 22.50|
|Beta (5Y monthly)||1.13|
|PE ratio (TTM)||N/A|
|Earnings date||22 Feb 2023 - 27 Feb 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||18.84|
N=1,172 Australian pain patientsDatapoints collected from commencing NanaBis™ (baseline) up to month 1255% improvement in pain relief75% of patients reduced their opioid use31% Improvements in Quality of Life as it relates to pain interference92% of patients with bone metastasis from cancer had reduced their pain severity and pain interference (Quality of Life) scores at 6-monthsNew “ENHANCE” study expects to onboard March 2023 Sydney, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Medlab Clinical Ltd (ASX:M
Medlab Clinical ( ASX:MDC ) Full Year 2022 Results Key Financial Results Revenue: AU$1.54m (up 110% from FY 2021). Net...
Every investor in Medlab Clinical Limited ( ASX:MDC ) should be aware of the most powerful shareholder groups. Large...